Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Today's Research Report Coverage on Medical Equipment Stocks -- Avinger, ViewRay, EnteroMedics, and Nevro

Chelmsford Park SA
Posted on: 19 Aug 17

NEW YORK, August 18, 2017 /PRNewswire/ --

If you want a Stock Review on AVGR, VRAY, ETRM, or NVRO then come over to and sign up for your free customized report today. The Medical Appliances and Equipment space primarily offers equipment and devices, which are designed for diagnosis, monitoring, and treatment of patients in healthcare systems worldwide. Firms in this industry research, develop, and manufacture primarily surgical, diagnostic, and orthopedic instruments. Pre-market, evaluates Avinger Inc. (NASDAQ: AVGR), ViewRay Inc. (NASDAQ: VRAY), EnteroMedics Inc. (NASDAQ: ETRM), and Nevro Corp. (NYSE: NVRO). Learn more about these stocks by signing up for their free reports on at:


On Thursday, shares in Redwood City, California headquartered Avinger Inc. recorded a trading volume of 368,547 shares. The stock ended the session 3.86% higher at $0.29. The Company's shares are trading 33.25% below their 50-day moving average. Moreover, shares of Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the US and Europe, have a Relative Strength Index (RSI) of 31.71.

On August 08th, 2017, Avinger reported results for Q2 ended June 30th, 2017. For Q2 2017, total revenue was $2.5 million; gross margin was (59)%; operating expenses were $9.8 million; loss from operations was $11.3 million; and adjusted EBITDA was a loss of $9.0 million. Cash and cash equivalents totaled $14.0 million as of June 30th, 2017, compared to $23.0 million as of March 31st, 2017. The free research report on AVGR is available at:


Bedford, Ohio headquartered ViewRay Inc.'s stock closed the day 4.51% lower at $5.29 with a total trading volume of 372,881 shares. The Company's shares have surged 69.01% since the start of this year. The stock is trading 1.78% below its 200-day moving average. Additionally, shares of ViewRay, which through its subsidiary, ViewRay Technologies, Inc., designs, manufactures, and markets radiation therapy systems, have an RSI of 43.54.

On August 07th, 2017, ViewRay announced financial results for Q2 and six months ended June 30th, 2017. For Q2 2017, total revenue was $0.7 million; cost of product revenue was $0.3 million; and total operating expenses were $12.6 million. For the six months ended June 30th, 2017, total revenue was $1.9 million; cost of product revenue was $0.6 million; and total operating expenses were $23.7 million. The complimentary report on VRAY can be downloaded at:


Shares in St. Paul, Minnesota headquartered EnteroMedics Inc. recorded a trading volume of 379,311 shares. The stock ended yesterday's trading session 2.03% lower at $1.93. The Company's shares are trading below their 50-day moving average by 55.78%. Furthermore, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have an RSI of 13.23.

On July 31st, 2017, EnteroMedics announced that it has received approval from the Ministry of Health, Social Services, and Equality in Spain through the Agency of Medicines and Medical Devices, and the CEIC Ethics Committee to initiate a clinical trial for the Gastric Vest™ System in Spain. The Company expects the safety and performance CE Mark study for the Gastric Vest to include a total of between 50 and 100 patients at up to four sites within the European Union. Visit us today and download our complete research report on ETRM for free at:


Redwood City, California headquartered Nevro Corp.'s stock finished Thursday's session 0.52% higher at $83.74 with a total trading volume of 392,609 shares. The Company's shares have advanced 7.93% over the previous three months and 15.25% since the start of this year. The stock is trading above its 50-day moving average by 4.70%. Additionally, shares of Nevro, which focuses on providing products for the patients suffering from chronic pain in the US and internationally, have an RSI of 53.40.

On August 07th, 2017, Nevro reported financial results for the three months ended June 30th, 2017. For Q2 2017, revenue was $78.0 million; gross profit was $53.9 million; operating expenses were $63.8 million; and loss from operations was $9.9 million. The Company also reiterated its expectations for worldwide revenue to be in the range of $310 million to $320 million for 2017. Get free access to your technical report on NVRO at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Editor's Details

Mike Wood

Last updated on: 19/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.